This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.
Here's Why You Should Retain CONMED (CNMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.
Masimo (MASI) Launches SuperSensor, Boosts Product Profile
by Zacks Equity Research
Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.
LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra
by Zacks Equity Research
According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
LHC Group (LHCG) to Boost Nationwide Presence With New Buyout
by Zacks Equity Research
LHC Group's (LHCG) deal win enables the company to acquire home health, hospice and therapy assets in 22 states.
Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes
by Zacks Equity Research
Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Omnicell (OMCL) New Buyout Expands Patient Engagement Suite
by Zacks Equity Research
With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.
NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics
by Zacks Equity Research
NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
by Zacks Equity Research
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
HSIC or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Enhances Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.
Reasons to Hold on to AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
SmileDirectClub (SDC) Struggles With New Markets, High Debt
by Zacks Equity Research
SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.
Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform
by Zacks Equity Research
Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.
Stryker (SYK) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.
TransMedics (TMDX) Receives FDA Nod for OCS Heart System
by Zacks Equity Research
TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.
Here's Why You Should Invest in Integer Holdings (ITGR) Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Medtronic's (MDT) Emprint Ablation System Study Data Positive
by Zacks Equity Research
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.
Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI
by Zacks Equity Research
Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.
Omnicell (OMCL) Opens New Software Development Center in India
by Zacks Equity Research
Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.